This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Ellen Corenswet
Ellen B. Corenswet
Senior Counsel
New York +1 212 841 1256 ecorenswet@cov.com Download V-card

Ellen Corenswet acts as outside corporate general counsel to emerging companies, principally in the life sciences and technology/media industries. She also represents traditional and corporate VCs in their financings. Her company clients range from early stage to public companies. Ms. Corenswet makes a personal commitment to each of her clients to spend the time to understand their business and objectives and to help them understand the issues they will face. Ms. Corenswet prides herself on the energy and enthusiasm she brings to helping her clients. She has been recognized as a leading lawyer by Legal 500 for her work in Venture Capital & Emerging Companies. and is a frequent speaker on legal panels and at conferences, particularly in the life sciences industry. Ms. Corenswet is on the Board of National Advisors of Springboard Enterprises, Inc. and has been a long-time advisor to Springboard companies in the life sciences, tech and digital health sectors. She is also on the Board of Directors of New York BIO.

Venture Capital Financings

  • IFM Therapeutics, Inc. (development stage biotechnology company) in its Series A Preferred Stock financing by Atlas Venture, Abingworth and Novartis.
  • KitCheck, Inc. (hospital medication tracking and restocking solutions) in its Series A, B and C Preferred Stock financings, led by New Leaf Ventures, Kaiser Permanente Ventures and Baxter Ventures.
  • Johnson & Johnson Development Corporation in preferred stock investments in a number of early stage biotechnology companies, including Padlock, Aduro and Torax Medical.
  • AstraZeneca in its Series D and Series E Preferred Stock investments in Moderna Therapeutics, Inc. (development of messenger RNA therapeutics).
  • MedImmune Ventures as the lead investor in a Series A Preferred Stock financing in G1 Therapeutics, Inc. (small molecule cancer therapy).
  • VantagePoint Venture Partners in numerous preferred stock financings.
  • TouchTunes Interactive Networks, Inc., the largest interactive entertainment platform, in its Series E Preferred Stock financing led by 3i Corporation.
  • Highbridge Principal Strategies in its minority investment in Revolt TV, a cable channel launched by Sean Combs.
  • Tracon Pharmaceuticals, Inc. in its recapitalization and Series A Preferred financing by Asian and European investors.

Mergers and Acquisitions

  • IFM Therapeutics, Inc., an early stage biotechnology company, in its sale to Bristol Myers Squib (comprised of IFM’s two oncology programs) and the spin out of IFM’s inflammation program to a newly-established company.
  • Acorda Therapeutics, Inc., a public specialty pharmaceutical company, in its acquisition of certain marketed and development-stage assets of NeurogesX Corporation.
  • TrioMed Innovations Corp. in its formation, venture financing and acquisition of assets of Safe Life Corp., an anti-microbial products company.
  • Memory Pharmaceuticals Corporation in its acquisition by Hoffman-La Roche Inc.

Capital Markets and Securities

  • Securities reporting and compliance advice to Acorda Therapeutics, Inc.
  • Securities compliance advice to a range of emerging companies.
  • IPOs of Acorda Therapeutics, Inc., Memory Pharmaceuticals Corporation and Traffic.com.

Pro Bono

  • Coalition for Queens, a non-profit organization whose mission is to build a tech community in Queens, including through its Access Code program that teaches low income individuals to code.
  • Plan International, Inc. in its acquisition of CEDPA (Centre for Population and Development Activities).
  • Congregation B’nai Jeshurun, as its general counsel.
  • Best Lawyers in America, Health Care (2013-2018)
  • Legal 500 US, Venture Capital & Emerging Companies (2012-2017)
  • LMG Life Sciences, "Life Science Star" (2013)